Biocon Ltd News

Biocon soars 10% in 3 days, stock nears 52-week high; here's why

In the past 12 trading days, the market price of Biocon has appreciated by 20 per cent from a level of ₹349.65 on the BSE on April 24, 2026.

Nifty, Bank Nifty strategy; 3 stock recommendations by Motilal Oswal

Chandan Taparia of Motilal Oswal decodes how to trade Nifty and Bank Nifty today; here are stock bets and strategy

Claire has what it takes to lead Biocon forward: Kiran Mazumdar-Shaw

Kiran Mazumdar-Shaw explained why she has chosen her niece, Claire, as her successor, outlining a five-year transition plan that will eventually see Claire take over as chairperson

Biocon eyes in-licensing opportunities to expand biosimilars portfolio

Biocon is scouting for biosimilar in-licensing opportunities while banking on multiple FY27 product launches to drive growth, margins, and market expansion

Biocon shares gain 3% despite 57% drop in Q4 profit; dividend announced

Bengaluru-based Biocon said that its Q4 profit stood at ₹198.6. The profit was hit by an exceptional item outgo of ₹80.4 crore on various heads, including the impact of the new labour code.

Biocon Q4 result: Profit down 56.8% at ₹198.6 cr; revenue at ₹4,516.6 cr

Biocon Ltd has reported a 56.8 per cent decline in consolidated net profit at Rs 198.6 crore in the fourth quarter ended March 31, hit by exceptional item outgo of Rs 80.4 crore on various heads, including impact of new labour code. The company had posted a consolidated net profit of Rs 459.4 crore in the corresponding period previous fiscal, Biocon Ltd said in a regulatory filing on Thursday. Consolidated revenue from operations in the fourth quarter was at Rs 4,516.6 crore as against Rs 4,417 crore in the year-ago period, it added. Total expenses in the fourth quarter were higher at Rs 4,241.2 crore as compared to Rs 3,987.5 crore in the same period a year ago, it said. The company's board has recommended a final dividend of 50 paise per equity share of face value of Rs 5 each for the financial year ended March 31, 2026, subject to shareholders' approval at the ensuing annual general meeting, Biocon said. For FY26, consolidated net profit was at Rs 368.8 crore, down from Rs 1,4

Stocks to Watch today: BSE, MRF, L&T, Paytm, Meesho, Biocon, Bajaj Auto

Stocks to Watch today, May 7, 2026: Mahindra Lifespaces, Deepak Fertilizers, Newgen Software, and Pidilite Industries are among the top stocks to watch today

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Kiran Mazumdar-Shaw names niece Claire Mazumdar as successor at Biocon

Biocon founder Kiran Mazumdar-Shaw outlines a five-year transition plan, naming niece Claire Mazumdar as successor to lead the company's next growth phase

Who is Claire Mazumdar, Kiran Mazumdar-Shaw's chosen successor for Biocon?

Claire Mazumdar, founding CEO of Bicara Therapeutics, has been named as successor to Biocon founder Kiran Mazumdar-Shaw, with a gradual leadership transition planned.

Biocon founder Kiran Mazumdar-Shaw picks niece Claire as successor

She plans a gradual leadership transition over the next five years, with her niece Claire Mazumdar expected to assume the chair in a phased manner

Stocks to Watch today: Rate sensitives, Infosys, Aurobindo Pharma, GAIL

Stocks to Watch today, April 8, 2026: Banks, Real estate, automobiles, Infosys, Aurobindo Pharma are some of the key stocks to watch today

Biocon shares slip 4% amid heavy volumes; 9.58 mn shares traded on NSE

According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were not known

Biocon seeks to be the top global insulin player as rivals turn to GLP-1

Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Nifty Pharma index falls for 4th day, sinks 4% as new US tariff risks mount

Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country

We've always been an India player, says Biocon MD Shreehas Tambe

Biocon Limited names Shreehas Tambe CEO, outlines AI-led, integration-driven strategy to boost global biosimilars and generics growth

Biocon appoints Shreehas Tambe as CEO & MD effective from April 1

Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.